BAYNES ROY D. sold 20.6% of their position (9.75K shares) of TRAVERE THERAPEUTICS, INC. on the open market
Open‑market sale worth $431.1K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 5/4/2026ACC: 0001680739-26-000007
-9.75K
Net shares
Net seller
$431.1K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
9.75K acquired · 19.50K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+9.75K
Price / share
$6.82
Trade value
$66.50K
% of position
26.0%
5/1/2026
37.50K→47.25K
Common Stock
Direct
Shares
−9.75K
Price / share
$44.22
Trade value
$431.14K
% of position
20.6%
5/1/2026
47.25K→37.50K
Total
Net shares
+0.00
Net value
-$364.65K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/1/2026 | M · Option Exercise | +9.75K | $6.82 | $66.50K | 26.0% | 37.50K | 47.25K |
| Common Stock Direct | 5/1/2026 | S · Sale | −9.75K | $44.22 | $431.14K | 20.6% | 47.25K | 37.50K |
| Total | +0.00 | -$364.65K | ||||||
Derivative Transactions1
Stock option (right to buy)
Direct
Converts to
Common Stock
9.75K shares
Shares
−9.75K
Strike price
6.82
Held after
9.75K
Exercisable
—
5/1/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock option (right to buy) Direct | Common Stock9.75K shares | 5/1/2026 | M · Option Exercise | −9.75K | 6.82 | — | 9.75K |